Listen to our CFO, Allan Shaw on this #BusinessOfBiotech podcast episode, where he and host Matthew Pillar discuss cash management and “runway preservation” for new and emerging biopharma companies, financing during clinical trials, managing funds and more here: https://brnw.ch/21wBHAU
Portage Biotech Inc
Biotechnology Research
Westport, CT 768 followers
Accelerating promising medicines that revolutionize treatment for patients with cancer
About us
Portage Biotech is clinical stage biopharmaceutical company driving the development of first-in-class immuno-oncology therapies to help more patients achieve durable treatment responses and a better quality of life. The Company is using its strong industry network and diverse drug platforms to identify novel assets and asset combinations.
- Website
-
http://www.portagebiotech.com/
External link for Portage Biotech Inc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Westport, CT
- Type
- Public Company
Locations
-
Primary
Get directions
Westport, CT, US
-
Get directions
Craigmuir Chambers, Road Town,
Tortola, British Virgin Islands VG1110 416.929.1806, VG
Employees at Portage Biotech Inc
Updates
-
In case you missed it, our CEO, Dr. Ian Walters was featured as an expert panelist along with other industry leaders at #BIO2023 to discuss #CheckpointInhibitors & progress in the #ImmunoOncology space, moderated by Ruojing (Angus) Liu of Fierce Biotech Learn more here: https://brnw.ch/21wBD9O
-
-
Our CEO, Dr. Ian Walters, weighed in on the influence that an increase in patient-centric concern has on Portage’s work with #ImmunoOncology treatments in this Pharma's Almanac roundtable. Read more about our #PrecisionOncology approach here: https://fal.cn/3AyBE
-
-
Check out our CEO, Ian Walters, M.D. featured in “The State of the Union in Cancer Innovation” piece by PM360 Magazine discussing exciting developments in precision #immuno-onoclogy including Portage’s current clinical programs: https://fal.cn/3zTfw
The State of the Union in Cancer Innovation
-
Dr. Nicholas Coupe, PI on our Phase 1/2 trial, discussed the investigation of our PORT-2 #iNKT engager in patients with advanced #melanoma or metastatic #NSCLC in this OncLive video. Learn more here: https://fal.cn/3zRgA
Dr Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC
onclive.com
-
Our CFO, Allan Shaw, connected with Wayne Koberstein of Life Science Leader Life Science Leader to discuss navigating the new bio funding challenges and risks. Read more about his thoughts on collaborations and considerations here: https://fal.cn/3zN5f
-
-
Congratulations to our collaborators, Intensity Therapeutics, Inc., on their successful upsized IPO! This is the second IPO from the Portage universe and we’re grateful to see the public markets are being more open to biotech offerings! Read more here: https://fal.cn/3zAXV
-
-
We’re excited to announce that we have dosed the first patient in our Phase 1a trial evaluating our best-in-class adenosine 2A receptor (A2AR) inhibitor in select solid tumors. We look forward to exploring our next-generation approach to target the adenosine pathway. Learn more about the trial here: https://fal.cn/3zoWa
-
-
While at #ASCO23, our CEO Dr. Ian Walters spoke with OncologyTube.com about Portage’s updated data on its invariant natural killer T cell engager for the treatment of #melanoma and #NSCLC. Learn more about the clinical trial and results here: https://fal.cn/3zhvA
IMM60 and Pembrolizumab Study for Advanced Melanoma & NSCLC
https://oncologytube.com/
-
The adenosine space is heating up with its own dedicated conference focused on novel ways to treat #cancer. Our CEO, Dr. Ian Walters will chair the first day of the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston and will help guide discussion on clinical progress. Learn more here: https://fal.cn/3zftk
-